FORBES-TATE for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/H.R. 1102]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 4438- American Research andCompetitiveness Act of 2014; Issues related to 340B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JERRY DRISCOLL | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
Trade (domestic/foreign) TRD
Trade related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JERRY DRISCOLL | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JERRY DRISCOLL | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.